These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 31411673

  • 1. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
    Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA.
    Hum Mol Genet; 2019 Nov 01; 28(21):3528-3542. PubMed ID: 31411673
    [Abstract] [Full Text] [Related]

  • 2. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
    Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA.
    Ann Neurol; 2015 Aug 01; 78(2):303-16. PubMed ID: 26010264
    [Abstract] [Full Text] [Related]

  • 3. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
    Kagiava A, Karaiskos C, Richter J, Tryfonos C, Jennings MJ, Heslegrave AJ, Sargiannidou I, Stavrou M, Zetterberg H, Reilly MM, Christodoulou C, Horvath R, Kleopa KA.
    Gene Ther; 2021 Nov 01; 28(10-11):659-675. PubMed ID: 33692503
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy.
    Kagiava A, Sargiannidou I, Theophilidis G, Karaiskos C, Richter J, Bashiardes S, Schiza N, Nearchou M, Christodoulou C, Scherer SS, Kleopa KA.
    Proc Natl Acad Sci U S A; 2016 Apr 26; 113(17):E2421-9. PubMed ID: 27035961
    [Abstract] [Full Text] [Related]

  • 7. Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.
    Kagiava A, Karaiskos C, Lapathitis G, Heslegrave A, Sargiannidou I, Zetterberg H, Bosch A, Kleopa KA.
    Mol Ther Methods Clin Dev; 2023 Sep 14; 30():377-393. PubMed ID: 37645436
    [Abstract] [Full Text] [Related]

  • 8. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
    Scherer SS, Xu YT, Messing A, Willecke K, Fischbeck KH, Jeng LJ.
    J Neurosci; 2005 Feb 09; 25(6):1550-9. PubMed ID: 15703409
    [Abstract] [Full Text] [Related]

  • 9. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
    Kyriakoudi S, Sargiannidou I, Kagiava A, Olympiou M, Kleopa KA.
    Hum Mol Genet; 2017 May 01; 26(9):1622-1633. PubMed ID: 28334782
    [Abstract] [Full Text] [Related]

  • 10. Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.
    Vavlitou N, Sargiannidou I, Markoullis K, Kyriacou K, Scherer SS, Kleopa KA.
    J Neuropathol Exp Neurol; 2010 Sep 01; 69(9):945-58. PubMed ID: 20720503
    [Abstract] [Full Text] [Related]

  • 11. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
    Freidin M, Asche-Godin S, Abrams CK.
    Exp Neurol; 2015 Jan 01; 263():339-49. PubMed ID: 25447941
    [Abstract] [Full Text] [Related]

  • 12. Two new mouse models of Gjb1-associated Charcot-Marie-Tooth disease type 1X.
    Tadenev ALD, Hatton CL, Pattavina B, Mullins T, Schneider R, Bogdanik LP, Burgess RW.
    J Peripher Nerv Syst; 2023 Sep 01; 28(3):317-328. PubMed ID: 37551045
    [Abstract] [Full Text] [Related]

  • 13. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
    Kleopa KA, Scherer SS.
    Neuromolecular Med; 2006 Sep 01; 8(1-2):107-22. PubMed ID: 16775370
    [Abstract] [Full Text] [Related]

  • 14. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ.
    Acta Neurol Scand Suppl; 2012 Sep 01; (193):iv-22. PubMed ID: 23106488
    [Abstract] [Full Text] [Related]

  • 15. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
    Kleopa KA, Abrams CK, Scherer SS.
    Brain Res; 2012 Dec 03; 1487():198-205. PubMed ID: 22771394
    [Abstract] [Full Text] [Related]

  • 16. Connexins, gap junctions and peripheral neuropathy.
    Kleopa KA, Sargiannidou I.
    Neurosci Lett; 2015 Jun 02; 596():27-32. PubMed ID: 25449862
    [Abstract] [Full Text] [Related]

  • 17. Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X.
    Kleopa KA, Zamba-Papanicolaou E, Alevra X, Nicolaou P, Georgiou DM, Hadjisavvas A, Kyriakides T, Christodoulou K.
    Neurology; 2006 Feb 14; 66(3):396-402. PubMed ID: 16476939
    [Abstract] [Full Text] [Related]

  • 18. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.
    Olympiou M, Sargiannidou I, Markoullis K, Karaiskos C, Kagiava A, Kyriakoudi S, Abrams CK, Kleopa KA.
    Acta Neuropathol Commun; 2016 Sep 01; 4(1):95. PubMed ID: 27585976
    [Abstract] [Full Text] [Related]

  • 19. GJB1-associated X-linked Charcot-Marie-Tooth disease, a disorder affecting the central and peripheral nervous systems.
    Abrams CK, Freidin M.
    Cell Tissue Res; 2015 Jun 01; 360(3):659-73. PubMed ID: 25370202
    [Abstract] [Full Text] [Related]

  • 20. X-linked Charcot-Marie-Tooth disease.
    Scherer SS, Kleopa KA.
    J Peripher Nerv Syst; 2012 Dec 01; 17 Suppl 3(0 3):9-13. PubMed ID: 23279425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.